Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent (RESOLUTE-AC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00617084 |
Recruitment Status :
Completed
First Posted : February 15, 2008
Results First Posted : May 17, 2011
Last Update Posted : June 6, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study.
Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Device: Medtronic Endeavor Resolute Device: Abbott Xience V | Phase 4 |
The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study.
Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population.
Study hypothesis: To determine whether the Zotarolimus-Eluting stent (Medtronic Endeavor-Resolute) is non-inferior to the Everolimus-eluting stent (Abbott XIENCE V) in terms of the primary endpoint at 12 months after stent implantation.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2292 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention |
Study Start Date : | April 2008 |
Actual Primary Completion Date : | May 2010 |
Actual Study Completion Date : | February 2014 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1. Resolute
Medtronic Endeavor Resolute
|
Device: Medtronic Endeavor Resolute
Medtronic Endeavor Resolute
Other Name: Endeavor Resolute Zotarolimus-Eluting Coronary Stent System |
Active Comparator: 2. XIENCE V
Abbott Xience V
|
Device: Abbott Xience V
Abbott Xience V
Other Name: XIENCE V Everolimus Eluting Coronary Stent System |
- Target Lesion Failure [ Time Frame: 12 months ]Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average.
- In-Stent Percent Diameter Stenosis [ Time Frame: 13 Months ]In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Minimal age 18 years
- Symptomatic coronary artery disease
- Patient acceptable candidate for treatment with drug eluting stent in accordance with applicable guidelines
- Presence of one or more coronary artery stenosis >50% with reference diameter 2.25-4.0mm which can be covered by one or multiple stents
- Patient indication, lesion length and vessel diameter according to 'Instructions for Use' of study stents
- Patient is willing and able to cooperate with study procedures and required follow up visits and patient or legal representative has been informed and agrees by signing EC approved written informed consent.
Exclusion Criteria:
- Women of childbearing potential who do not have a negative pregnancy test within 7 days before procedure and women who are lactating
- Known intolerance to aspirin, clopidogrel or ticlopidin, heparin, cobalt, nickel, chromium, molybdenum, polymer coatings, Zotarolimus, Everolimus, or contrast material
- Participating in other trial before reaching primary endpoint
- Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00617084
Switzerland | |
Stiftung Inselspital, Department of Cardiology | |
Bern, Switzerland, CH-3010 |
Principal Investigator: | Patrick Serruys, MD | Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands | |
Principal Investigator: | Sigmund Silber, MD | Kardiologische Praxis und Praxisklinik, Munich, Germany | |
Principal Investigator: | Stephan Windecker, MD | University Hospital Bern, Bern, Switzerland |
Responsible Party: | Medtronic Vascular |
ClinicalTrials.gov Identifier: | NCT00617084 |
Other Study ID Numbers: |
Version 1.2 - IP090 |
First Posted: | February 15, 2008 Key Record Dates |
Results First Posted: | May 17, 2011 |
Last Update Posted: | June 6, 2014 |
Last Verified: | May 2014 |
Drug Eluting Stents Interventional Cardiology |
Coronary Artery Disease Coronary Disease Myocardial Ischemia Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
Vascular Diseases Everolimus Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |